A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.

Toshio Shimizu Yasutoshi Kuboki Chia-Chi Lin Kan Yonemori Tomoko Yanai Douglas V Faller Lwona Dobler Neeraj GuptaFarhad SedaratiKyu-Pyo Kim

Published in: Targeted oncology (2021)

NCT03370302; Registered December 7, 2017.

Keyphrases